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Long-Term Outcomes of Cardiac Resynchronization Therapy Using
Apical Versus Nonapical Left Ventricular Pacing
Francisco Leyva, MD; Abbasin Zegard, MB, ChB; Robin J. Taylor, MRCP; Paul W. X. Foley, MD; Fraz Umar, MB, ChB; Kiran Patel, PhD;
Jonathan Panting, MB, ChB; Peter van Dam, PhD; Frits W. Prinzen, PhD; Howard Marshall, PhD; Tian Qiu, MD
Background-—Experimental evidence indicates that left ventricular (LV) apical pacing is hemodynamically superior to nonapical LV
pacing. Some studies have shown that an LV apical lead position is unfavorable in cardiac resynchronization therapy. We sought to
determine whether an apical LV lead position inﬂuences cardiac mortality after cardiac resynchronization therapy.
Methods and Results-—In this retrospective observational study, the primary end point of cardiac mortality was assessed in
relation to longitudinal (basal, midventricular, or apical) and circumferential (anterior, lateral, or posterior) LV lead positions, as well
as right ventricular (apical or septal), assigned using ﬂuoroscopy. Lead positions were assessed in 1189 patients undergoing
cardiac resynchronization therapy implantation over 15 years. After a median follow-up of 6.0 years (interquartile range: 4.4–7.7
years), an apical LV lead position was associated with lower cardiac mortality than a nonapical position (adjusted hazard ratio:
0.74; 95% conﬁdence interval, 0.56–0.99) after covariate adjustment. There were no differences in total mortality or heart failure
hospitalization. Death from pump failure was lower with apical than nonapical positions (adjusted hazard ratio: 0.69; 95%
conﬁdence interval, 0.51–0.94). Compared with a basal position, an apical LV position was also associated with lower risk of
sudden cardiac death (adjusted hazard ratio: 0.34; 95% conﬁdence interval, 0.13–0.93). No differences emerged between
circumferential LV lead positions or right ventricular positions with respect to any end point.
Conclusions-—In recipients of cardiac resynchronization therapy, an apical LV lead position was associated with better long-term
cardiac survival than a nonapical position. This effect was due to a lower risk of pump failure and sudden cardiac death. ( J Am
Heart Assoc. 2018;7:e008508. DOI: 10.1161/JAHA.117.008508.)
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C ardiac resynchronization therapy (CRT), with deﬁbrilla-tion (CRT-D) or without (CRT with pacing), is a standard
treatment for selected patients with systolic heart failure (HF)
and a wide QRS duration.1 As is the case with any other
medical therapy, the response to CRT is variable. The
“nonresponder” rate is said to be around 30%, depending
on how response is deﬁned.
The position of the left ventricular (LV) lead has been
implicated in the variable outcomes of CRT; however, no
randomized controlled trial has addressed this issue. A
subanalysis of the MADIT-CRT (Multicenter Automatic Deﬁbril-
lator Implantation Trial–Cardiac Resynchronization Therapy)
trial, apical LV lead positions were less favorable than basal or
mid-LV lead positions in terms of total mortality and HF
hospitalization.2 Similar ﬁndings emerged from a subanalysis of
the REVERSE (Resynchronization Reverses Remodeling in
Systolic Left Ventricular Dysfunction) trial.3 These ﬁndings
are counterintuitive, as previous experimental and clinical
evidence shows that an apical LV lead position is more
favorable than nonapical positions.4,5 During normal sinus
rhythm in intact myocardium, electrical impulses travel through
the rapid conduction system from the His bundle toward the
low apex. Thereafter, LV activation proceeds from apex to base
as impulses exit the Purkinje system into the slower conducting
working myocardium.6 Pacing at the LV apex would thus be
expected to provide a near-physiological sequence of activa-
tion. Although an LV apical position may seem anatomically
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close to a right ventricular (RV) apical lead, the longest
electrical delay usually occurs across the interventricular
septum. Because the apex is thinner, apical pacing could
arguably provide more rapid capture by the endocardium and
Purkinje network, which is known to provide the fast apex-to-
base activation that occurs in the normal heart. We should
consider that when CRT is delivered when the atrioventricular
delay is shorter than intrinsic PR interval, the ventricular
activation sequence is completely determined by the pacing-
induced activation wave fronts. Computer modeling studies
support the notion that LV lead positioning should be guided
by what is most physiologically close to normal activation
rather than targeting the latest activated region.7 In this
regard, van Deursen et al used a canine left bundle-branch
block (LBBB) model to show that the highest hemodynamic
response during CRT, measured using the rate of rise of LV
pressure (LV dP/dt), occurred with LV apical positions rather
than with basal and midventricular positions.4 Other pacing
studies have shown similar ﬁndings.5 Although conduction in
intact myocardium is not the same as in scarred myocardium,
acute studies in humans show a similar picture. We observed
better hemodynamic response from LV apical pacing com-
pared with basal LV pacing in patients with ischemic
cardiomyopathy and LBBB.8
Arguably, a link between the physiological effects of LV
position and outcomes should perhaps focus on cardiac
outcomes rather than total mortality. In this study of real-
world clinical practice, we compared cardiac mortality and
total mortality after CRT according to apical and nonapical LV
lead positions. We also assessed clinical outcomes according
to circumferential LV lead positions and RV lead positions.
Methods
This retrospective study included patients from 2 centers
(Good Hope Hospital and Queen Elizabeth Hospital,
Birmingham, United Kingdom). The study was approved by
the local ethics committee or clinical audit departments in the
2 institutions. The requirement for patient informed consent
was waived in the case of clinical audits. The data, analytic
methods, and study materials will not be made available to
other researchers for purposes of reproducing the results or
replicating the procedure.
Patients
Inclusion criteria were as follows: systolic HF in New York Heart
Association (NYHA) classes I to IV; maximum tolerated
treatment with angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers, b-blockers, and mineralocor-
ticoid receptor antagonists; QRS duration ≥120 ms; LV ejec-
tion fraction (LVEF) ≤35%; and use of a unipolar or bipolar LV
lead in CRT implantation. Exclusion criteria were as follows:
contraindications to cardiac pacing; myocardial infarction or
acute coronary syndrome within the previous month; severe
structural valvular heart disease; and presence of comorbidities
likely to threaten survival for 12 months. The diagnosis of HF
was based on echocardiographic evidence of LV systolic
dysfunction. The diagnosis of ischemic cardiomyopathy was
based on the ﬁndings of systolic dysfunction on echocardio-
graphy if LV systolic dysfunction was associated with a
myocardial infarction or in the background of angiographically
signiﬁcant coronary artery disease. Late gadolinium enhance-
ment cardiovascular magnetic resonance was also used to
determine the etiology of HF. The study conforms with the
Declaration of Helsinki and was approved by the local clinical
audit departments and/or ethics committee.
Device therapy
Device implantation was undertaken using standard transve-
nous techniques under local anesthesia and intravenous
sedation. Subsequently, patients were followed up in ded-
icated device clinics. Up to 2013, patients in sinus rhythm
underwent transmitral Doppler-directed optimization of atri-
oventricular delay using an iterative technique before dis-
charge and at every scheduled visit thereafter. Thereafter,
routine echocardiographic optimization was abandoned and
undertaken only in symptomatic nonresponders. Backup atrial
pacing was set at 60 beats/min, and the pacing mode was
set to DDDR with an interventricular delay of 0 to 20 ms (LV
ﬁrst), according to clinician’s discretion. In patients with
permanent atrial ﬁbrillation, RV and LV leads were implanted
and a CRT generator was used, plugging the atrial port and
programming to a ventricular triggered mode. Atrioventricular
junction ablation was undertaken according to physicians’
decision. Patients underwent a clinical assessment on the day
before implantation and at 1, 3, and every 6 months following
device implantation.
Clinical Perspective
What Is New?
• In recipients of cardiac resynchronization therapy, an apical
left ventricular lead position was associated with better
long-term cardiac survival than a nonapical position. This
effect was due to a lower risk of pump failure and sudden
cardiac death.
• No difference in outcomes was observed among anterior,
posterior, and lateral left ventricular lead positions.
What Are the Clinical Implications?
• An apical left ventricular lead position in cardiac resynchro-
nization therapy is more favorable than a nonapical position.
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The United Kingdom National Institute of Clinical Excel-
lence guidelines in 2007 recommended CRT with pacing
rather than CRT-D for patients with nonischemic cardiomy-
opathy and indications for CRT. With a subsequent guideline
change in 2014 recommending CRT-D in nonischemic
cardiomyopathy,9 the proportion of CRT-D recipients
increased thereafter.
Lead position
We adopted the same system for LV lead tip position
described by the MADIT-CRT study group.2 Accordingly,
coronary sinus venograms undertaken at the time of implan-
tation were used retrospectively to assign the position of the
LV lead tip, as shown in Figure 1. For data analysis, the
anterolateral, lateral, and posterolateral sectors were grouped
together as the lateral wall and the basal and midventricular
sectors were grouped as nonapical. RV lead positions were
classiﬁed as apical or nonapical, which included low-, mid-,
and high-septal positions. All LV lead positions were assessed
retrospectively by an experienced implanter (F.L.) who was
blinded to clinical outcome data.
End Points
The primary end point was cardiac mortality, which included
cardiac transplantation or implantation of a ventricular assist
device. The secondary end point was total mortality. Ancilliary
end points included the composite end point of total mortality
or HF hospitalization; the composite end point of total
mortality or unplanned hospitalization for major adverse
cardiac events, which included hospitalization for HF,
Lateral
Lateral
Anterior
Anterolateral
Lateral
Posterolateral
Posterior
RV LV
LV
LONGITUDINAL POSITION
CIRCUMFERENTIAL POSITION
RAO
LAO
Figure 1. Assessment of LV lead position using ﬂuoroscopy. Longitudinal LV lead positions were assigned using the 30° RAO ﬂuoroscopic
view at the time of implantation, into basal, mid and apical. These correspond to the sectors shown in the 3-dimensional long axis envelope and
cross section (upper panel). Circumferential LV lead positions were assigned using the 30° LAO ﬂuoroscopic view into anterior, anterolateral,
lateral, posterolateral and posterior sectors, as shown in the short axis envelope and cross-section (lower panel). LAO indicates left anterior
oblique; LV, left ventricular; RV, right ventricular; RAO, right anterior oblique.
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myocardial infarction, acute coronary syndrome, and arrhyth-
mia (ventricular tachycardia, ventricular ﬁbrillation, and atrial
ﬁbrillation). Stroke and pulmonary embolism were not
considered major adverse cardiac events. For composite
end points, the ﬁrst event was included in statistical analyses.
Mortality data were collected through medical records and, as
appropriate, from interviews with patients’ caregivers. Clinical
outcome data were collected every 6 months by investigators
who were blinded to clinical and imaging data.
Mode of death
A “natural, unexpected death due to cardiac causes, heralded
by an abrupt loss of consciousness within 1 hour of the onset
of acute symptoms”10 was regarded as sudden cardiac death
(SCD). Death from pump failure was deﬁned as “death after a
period of clinical deterioration in signs and symptoms of HF
despite medical treatment.”11 Cause of death was adjudi-
cated on the basis of hospital records or documentation in
death certiﬁcates or primary care records. Deaths were
classiﬁed as unknown if no deﬁnitive data were found in
hospital or primary care records or from interviews with
caregivers. When a speciﬁc mode of death was considered
(pump failure or SCD), deaths from other causes were
censored.
Statistical Analysis
Continuous variables are expressed as meanSD. Normality
was tested using the Shapiro–Wilk test. Comparisons
between normally distributed continuous variables were made
using ANOVA, and categorical variables were analyzed using
v2 tests. To be able to compare our ﬁndings with those of
MADIT-CRT,2 we followed statistical analyses. Kaplan–Meier
curves and the log-rank test were used to assess observed
cumulative survival. Cox proportional hazards models were
used to assess relative risks. Proportionality hypotheses were
veriﬁed by visual examination of log (survival) graphs to
ensure parallel slopes and by examining Schoenfeld residuals.
Variables reaching P<0.10 on univariable analyses and
variables known to inﬂuence clinical outcomes after CRT,
such as age, sex, LVEF (<25%), QRS duration (QRS ≥150 ms),
QRS morphology (LBBB), HF etiology, NYHA class, diabetes
mellitus, and atrial ﬁbrillation, were entered in multivariable
models. Statistical analyses were performed using Stata 14
(StataCorp). A 2-tailed P<0.05 was considered statistically
signiﬁcant.
Results
This study included 1189 patients who underwent CRT device
implantation in 2 centers (Queen Elizabeth Hospital and Good
Hope Hospital, Birmingham, United Kingdom) over a period of
15 years, from August 2000 to July 2015. Over a follow-up
period of 6.0 years (median; interquartile range: 4.4–7.7
years), 633 of 1189 patients (53.2%) died. The cause of death
was unknown for 167 patients. Cardiac mortality affected 357
of 1189 patients (30.0%), and among these, 305 deaths (85%)
were due to pump failure and 44 (12%) were SCDs.
Longitudinal Position
Longitudinally, LV lead positions were as follows: 311 patients
(26.2%) had leads in basal positions, 604 (50.8%) had them in
midventricular positions, and 274 (23.0%) had them in apical
positions. A total of 915 (77%) patients had leads in nonapical
positions (basal plus midventricular). As shown in Table 1,
patients with LV apical and nonapical positions were well
matched for age, sex, HF etiology, comorbidities, atrial
rhythm, QRS duration, QRS morphology, upgrade from
pacemaker, LVEF, and medical therapy. Signiﬁcant differ-
ences emerged with respect to NYHA class and device type
between LV apical and nonapical positions, insofar as patients
with an apical position were more likely to be in NYHA class III
than in NYHA class IV. In addition, patients with apical lead
positions were more likely to receive CRT-D rather than CRT
with pacing (P=0.012).
In Kaplan–Meier survival analyses (Figure 2), an LV apical
position was associated with lower cardiac mortality than a
nonapical position (P=0.003). The annualized cardiac mortal-
ity death rates were highest with basal positions (8.7%),
intermediate with midventricular positions (6.6%), and lowest
with apical positions (4.9%; Table 2). Univariable analyses of
outcomes according to individual LV lead positions are shown
in Table 3. In multivariable analyses including NYHA class and
device type as well as other variables, an LV apical position
was associated with lower cardiac mortality than a nonapical
position (adjusted hazard ratio [HR]: 0.74; 95% conﬁdence
interval [CI], 0.56–0.99; Table 4). In a multivariable analysis
including only NYHA class (class IV compared with NYHA
classes I, II, and III) and device type (CRT-D or CRT with
pacing) as covariates, an LV apical position was associated
with lower cardiac mortality than a nonapical position
(adjusted HR: 0.72; 95% CI, 0.54–0.96; P=0.026). No
differences emerged with respect to total mortality and HF
hospitalization or total mortality and major adverse cardiac
events (Figure S1).
There were no signiﬁcant differences in total mortality
according to longitudinal LV lead position, although survival
curves began to separate around year 7 in favor of an LV
apical position (Figure 2). No differences emerged with
respect to the composite end points of total mortality and
HF hospitalization or to total mortality or HF hospitalization
separately (Figure S1).
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With respect to mode of death, pump failure was lower
with an LV apical position than with nonapical positions
when SCD was considered censored (adjusted HR: 0.69; 95%
CI, 0.51–0.94; Figure 3), and a graded risk was observed for
basal, midventricular, and apical LV lead positions (Figure S2).
Although no differences in SCD emerged with between LV
apical and nonapical lead positions (P=0.089; Figure 3), a
signiﬁcantly lower risk of SCD was observed with an LV
Table 1. Baseline Characteristics by Longitudinal LV Lead Position
Basal Mid Apical P Value Apical Nonapical P Value*
N 311 604 274 274 915
Sex (male), n (%) 226 (72.67) 453 (75) 204 (74.45) 0.744 204 (74.45) 679 (74.21) 0.935
Age, y 70.910.6 72.411 72.110.7 0.139 72.110.7 71.910.9 0.741
≤59 48 (15.43) 78 (12.91) 38 (13.87) 0.541 38 (13.87) 126 (13.77) 0.997
60–69 88 (28.30) 149 (24.67) 70 (25.55) 70 (25.55) 237 (25.90)
70–79 113 (36.33) 221 (36.59) 99 (36.13) 99 (36.13) 334 (36.50)
≥80 62 (19.94) 156 (25.83) 67 (24.45) 67 (24.45) 218 (23.83)
NYHA class, n (%)
I 4 (1.32) 21 (3.60) 13 (4.87) <0.001 13 (4.87) 25 (2.82) 0.012
II 8 (2.63) 47 (8.06) 22 (8.24) 22 (8.24) 55 (6.20)
III 237 (77.96) 455 (78.04) 214 (80.15) 214 (80.15) 692 (78.02)
IV 55 (18.09) 60 (10.29) 18 (6.74) 18 (6.74) 115 (12.97)
Device type, n (%)
CRT-D 100 (32.15) 278 (46.03) 136 (49.64) <0.001 136 (49.64) 378 (41.31) 0.015
CRT-P 211 (67.85) 326 (53.97) 138 (50.36) 138 (50.36) 537 (58.69)
Upgrade from pacemaker 40 (12.86) 119 (19.70) 44 (16.06) 0.030 44 (16.06) 159 (17.38) 0.611
Etiology of cardiomyopathy, n (%)
Ischemic 184 (59.16) 321 (53.15) 151 (55.11) 0.222 151 (55.11) 505 (55.19) 0.981
Nonischemic 127 (40.84) 283 (46.85) 123 (44.89) 123 (44.89) 410 (44.81)
Comorbidities, n (%)
Diabetes mellitus 62 (19.94) 134 (22.30) 61 (22.26) 0.688 61 (22.26) 196 (21.49) 0.786
Hypertension 81 (26.05) 179 (29.78) 80 (29.20) 0.484 80 (29.20) 260 (28.51) 0.825
CABG 62 (19.94) 112 (18.64) 49 (17.88) 0.809 49 (17.88) 174 (19.08) 0.657
ECG variables
Sinus rhythm, n (%) 217 (69.77) 395 (65.40) 184 (67.15) 0.410 184 (67.15) 612 (66.89) 0.934
Atrial fibrillation, n (%)† 94 (30.23) 209 (34.60) 90 (32.85) 90 (32.85) 303 (33.11)
QRS morphology (LBBB), n (%)‡ 224 (73.68) 487 (83.97) 220 (83.33) 0.001 220 (83.33) 711 (80.43) 0.290
QRS duration (ms)‡ 153.922.4 155.922.4 155.623.2 0.463 155.623.2 155.222.4 0.799
Medication, n (%)
Loop diuretics 275 (88.42) 579 (95.86) 264 (96.35) <0.001 264 (96.35) 854 (93.33) 0.064
ACEI/ARB 279 (89.71) 515 (85.26) 235 (85.77) 0.160 235 (85.77) 794 (86.78) 0.668
b-blockers 196 (63.02) 412 (68.21) 190 (69.34) 0.192 190 (69.34) 608 (66.45) 0.371
MRA 117 (37.62) 258 (42.72) 128 (46.72) 0.081 128 (46.72) 375 (40.98) 0.092
LVEF (%) 23.49.4 24.79.5 24.610.2 0.224 24.610.2 24.39.5 0.717
Variables are expressed as meanSD unless indicated otherwise. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery
bypass grafting; CRT-D, cardiac resynchronization therapy with deﬁbrillation; CRT-P, cardiac resynchronization therapy with pacing; LBBB, left bundle-branch block; LV, left ventricular;
LVEF, left ventricular ejection fraction; mid, midventricular; MRA, mineralocorticoid receptor antagonist.
*Refers to differences between the groups from ANOVA for continuous variables and from v2 tests for categorical variables.
†Includes permanent, persistent, and paroxysmal atrial ﬁbrillation.
‡Excludes upgrades to pacemaker.
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apical position compared with a basal LV lead position
(adjusted HR: 0.34; 95% CI, 0.13–0.93; Figure 3). In a
sensitivity analysis, similar results emerged when deaths
from pump failure and SCD were considered as competing
risks (Figure S3).
In subgroup analyses, male sex, the age stratum of 60 to
69 years, NYHA class III, CRT-D, ischemic etiology, no
diabetes mellitus, QRS ≥150 ms, and LBBB were associated
with lower cardiac mortality with an LV apical position
(Figure 4A). With respect to total mortality, an LV apical
position was superior to a nonapical position only in the age
stratum of 60 to 69 years, not in other subgroups (Figure 4b).
Circumferential Position
Circumferentially, LV lead positions were as follows: 100 of
1189 patients (8.41%) had leads in anterior positions; 1027 of
1189 (86.4%) had them in lateral positions, and 62 of 1189
(5.21%) had them in posterior positions (Table 5). Patients
with the different LV circumferential positions were well
matched for age, sex, NYHA class, device type, upgrade from
pacemaker, HF etiology, atrial rhythm, QRS duration, QRS
morphology, LVEF, and medical therapy, except mineralocor-
ticoid receptor antagonists, the uptake of which was higher in
lateral positions (P=0.007). There was a lower proportion of
hypertensive patients among those with LV posterior
positions.
In univariable analyses, no differences emerged between
circumferential positions with respect to cardiac mortality or
total mortality (Figure 5) or the composite end points
(Tables 2 and 3, and Figure S1).
RV Lead Positions
Cardiac mortality (univariate HR: 1.19; 95% CI, 0.83–1.70) and
total mortality (univariate HR: 1.03; 95% CI, 0.80–1.33) in
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Figure 2. Outcomes according to longitudinal left ventricular lead position. Kaplan–Meier survival curves for cardiac mortality and total
mortality according to apical and basal or midventricular (mid; grouped as nonapical) left ventricular lead positions.
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patients with an apical RV lead position were no different from
those in patients with a nonapical RV lead position.
Discussion
This study of LV lead positions in CRT provides the highest
number of patients and the longest follow-up compared with
subanalyses of randomized controlled trials or observational
studies to date. Several ﬁndings have emerged. First, an LV
apical lead position was associated with lower cardiac
mortality than nonapical positions over a median follow-up
period of 6 years. This effect was mediated by both pump
failure and SCD. Second, total mortality and HF hospitalization
were similar in LV apical and nonapical lead positions. Third,
no difference in these outcomes was observed among
anterior, posterior, and lateral LV lead positions. Fourth, no
difference in outcomes emerged between apical and septal RV
lead positions.
Apical Versus Nonapical LV Lead Position
The cause and mode of death were not considered in either
MADIT-CRT2 or REVERSE.3 Our ﬁnding of lower cardiac
mortality as well as death from pump failure with an apical LV
lead position is in keeping with experimental and clinical
studies showing that LV apical pacing is physiologically
superior to nonapical pacing.4,5
The observed beneﬁcial effect of LV apical pacing in CRT,
in terms of total mortality or HF hospitalization, is at odds with
a subanalysis of MADIT-CRT, in which an apical LV lead
position, compared with a nonapical position (basal or mid),
was associated with an increased risk of total mortality (HR:
2.91) as well as the combined end point of total mortality or
HF hospitalization (HR: 1.72) among a subset of 799 patients
followed up over 2.4 years.2 In the REVERSE trial,3 comprising
a subset of 346 patients and a follow-up of 1.05 years, an LV
nonapical lead position was associated a lower risk of total
mortality or HF hospitalization compared with an LV apical
position (HR 0.27). We should consider, however, that in the
subanalyses of these randomized controlled trials, outcomes
were reported in relation to other CRT patients with other LV
lead positions. It follows that such subanalyses were not
subject to the intended randomization rule of the trial.
Consequently, these subanalyses should be regarded as
“observational,” as is the present study.
In MADIT-CRT, worse outcomes from an LV apical position
were restricted to patients with LBBB.2 In contrast, we found
Table 2. Event Rates According to LV Lead Position
Cardiac Mortality Total Mortality HF Hospitalization
n (%) n (%) n (%)
Longitudinal position
Basal 137 (8.7) 192 (12.2) 61 (4.2)
Mid 163 (6.6) 306 (12.4) 106 (4.7)
Apical 57 (4.9) 135 (11.5) 43 (4.0)
Nonapical 300 (7.4) 498 (12.3) 167 (4.5)
Circumferential position
Anterior 37 (7.8) 61 (12.9) 15 (3.5)
Lateral 303 (6.8) 542 (12.2) 184 (4.5)
Posterior 17 (5.9) 30 (10.3) 11 (4.1)
Data are expressed as number of events during the follow-up period and annualized
event rates (%). HF indicates heart failure; LV, left ventricular; mid, midventricular.
Table 3. Univariable Analyses of LV Lead Positions in
Relation to Cardiac Mortality
LV Lead Position HR 95% CI P Value
Apical vs nonapical 0.66 0.49 0.87 0.003
Apical vs basal 0.55 0.40 0.75 <0.001
Apical vs mid 0.75 0.55 1.01 0.060
Mid vs basal 0.75 0.59 0.94 0.013
Posterior vs anterior 0.75 0.42 1.33 0.327
Lateral vs anterior 0.87 0.62 1.23 0.426
Total mortality or HF hospitalization
Apical vs nonapical 0.91 0.76 1.10 0.343
Apical vs basal 0.90 0.73 1.12 0.347
Apical vs mid 0.93 0.76 1.13 0.443
Mid vs basal 0.99 0.83 1.18 0.874
Posterior vs anterior 0.85 0.56 1.29 0.448
Lateral vs anterior 0.93 0.72 1.20 0.590
Total mortality
Apical vs nonapical 0.93 0.77 1.12 0.445
Apical vs basal 0.91 0.73 1.14 0.416
Apical vs mid 0.95 0.77 1.16 0.586
Mid vs basal 0.98 0.82 1.18 0.848
Posterior vs anterior 0.82 0.53 1.26 0.360
Lateral vs anterior 0.93 0.72 1.22 0.608
HF hospitalization
Apical vs nonapical 0.88 0.63 1.23 0.446
Apical vs basal 0.87 0.58 1.28 0.469
Apical vs mid 0.88 0.61 1.25 0.465
Mid vs basal 1.01 0.74 1.39 0.947
Posterior vs anterior 1.23 0.57 2.69 0.597
Lateral vs anterior 1.25 0.74 2.11 0.410
Results are presented in terms of HR and 95% CI from Cox proportional hazards
analyses. CI indicates conﬁdence interval; HF, heart failure; HR, hazard ratio; LV, left
ventricular; mid, midventricular.
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that, in terms of cardiac mortality, an LV apical position is
better in the context of LBBB or QRS ≥150 ms. In this
context, evidence suggests that not all LV apical lead
positions are unfavorable. Addressing whether effects of
apical LV pacing should vary according to level of conduction
block in a study that followed the MADIT-CRT subanalysis,
Kandala et al12 showed that a longer LV electrical delay in
apically positioned LV leads was associated with more
favorable LV reverse remodeling and lower risk of total
mortality or HF hospitalization compared with apically posi-
tioned LV leads with shorter LV electrical delays. Although
this study did not compare outcomes with those of nonapi-
cally positioned leads, it nevertheless shows that not all apical
lead positions have the same effect on outcomes. In the
present study, Q-LV was not systematic in choosing LV lead
positions.
Among the notable differences between the MADIT-CRT
patient population and the present cohort is the fact that all
patients in MADIT-CRT were in NYHA class I or II,2 which
compares with 13.1% in the present study. We observed
signiﬁcantly lower cardiac mortality with apical LV lead
positions in patients in NYHA class III (HR: 0.63; 95% CI,
0.46–0.88) but not in NYHA classes I and II. This suggests an
interaction between LV lead position and the severity of HF,
according to which an apical lead position is only neutral or
“detrimental” in mild HF. Clearly, however, this interaction can
be explored only in a study that includes patients with mild
and severe HF.
In MADIT-CRT, the extent of CRT beneﬁt was similar among
all lead positions in patients with nonischemic cardiomyopa-
thy and patients with ischemic cardiomyopathy in NYHA
class II.2 We found that an apical LV lead position had no
signiﬁcant effect on cardiac mortality in nonischemic car-
diomyopathy, but lower cardiacmortality was found in ischemic
cardiomyopathy. In this respect, we have previously shown that
an LV lead positioned over a myocardial scar was associated
with >6-fold increase in the risk of cardiovascular death.13 In
the present study, we did not explore LV position in relation to
myocardial scar. It is likely, however, that LV lead position is
more crucial in patients with ischemic cardiomyopathy, which is
typically more heterogeneous than nonischemic cardiomyopa-
thy with respect to the distribution of myocardial scar.
Circumferential Position
Early CRT studies showed that a lateral or posterolateral LV
lead position was associated with a superior hemodynamic
beneﬁt than anterior positions.14 Other clinical studies,
however, have not been consistent. Gasparini et al found no
difference in NYHA class, 6-minute walking distance, or LVEF
between anterior and posterolateral LV lead positions.15
Similar survival was observed for anterior and posterolateral
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Figure 3. Mode of death according to longitudinal LV lead position. Kaplan–Meier survival curves for death from pump failure and sudden
cardiac death to apical and basal or midventricular (mid; grouped as nonapical) LV lead positions. LV indicates left ventricular.
Table 4. Multivariable Analyses of LV Lead Positions in
Relation to Cardiac Mortality
HR 95% CI P Value
Apical vs nonapical 0.74 0.56 0.99 0.045
Sex, male 1.62 1.24 2.13 <0.001
Age, y 1.02 1.01 1.04 <0.001
NYHA class (IV) 2.06 1.57 2.70 <0.001
Device type (CRT-D) 0.67 0.53 0.86 0.002
Etiology (ischemic) 1.33 1.05 1.69 0.019
Diabetes mellitus 1.31 1.02 1.67 0.033
QRS morphology (LBBB) 0.62 0.48 0.79 <0.001
Loop diuretics 2.43 1.20 4.93 0.014
ACEI/ARB 0.69 0.50 0.94 0.020
Variables are expressed as HR and 95% CI. ACEI indicates angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker; CI, conﬁdence interval; CRT-D,
cardiac resynchronization therapy with deﬁbrillation; HR, hazard ratio; LBBB, left bundle-
branch block; LV, left ventricular; NYHA, New York Heart Association.
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LV lead positions in other observational studies16 and in the
COMPANION (Comparison of Medical Therapy, Pacing, and
Deﬁbrillation in Heart Failure) study.17 These ﬁndings are
consistent with our observation that circumferential position
has no impact on long-term clinical outcomes.
RV Lead Position
The meta-analysis of Zografos et al18 found similar changes in
LV end-systolic volume and functional status in RV apical versus
nonapical lead positions in CRT. Importantly, however, hard end
points were not addressed, given unacceptable study hetero-
geneity. In the REVERSE trial, no differences in a composite
clinical score were observed between RV apical and nonapical
lead positions.3 In the SEPTAL-CRT (SEPTAL-cardiac resyn-
chronization therapy) study,19 the LV reverse remodeling
response as well as total mortality or HF hospitalization were
similar with RV apical and nonapical lead positions. The present
study adds further evidence for a lack of inﬂuence on outcomes
of RV pacing site (apical or septal) in CRT.
LVEF
QRS Duration
QRS Morphology
Comorbidity
Etiology
Device Type
NYHA Class
Age
Sex
Subgroup
Overall
≤0.25
>0.25
<150
≥150
LBBB
Non-LBBB
Diabetes
Non-Diabetes
Ischaemic
Non-ischaemic
CRT-D
CRT-P
NYHA IV
NYHA III
NYHA I, II
≥80
70-79
60-69
≤59
Male
Female
No. of pts
1189
626
397
435
726
931
217
257
929
656
533
514
675
133
906
115
285
433
307
164
883
306
Hazard Ratio (95% CI)
0.66 (0.49, 0.87)
0.74 (0.51, 1.08)
0.60 (0.36, 1.03)
0.82 (0.55, 1.24)
0.55 (0.37, 0.81)
0.62 (0.44, 0.87)
0.80 (0.46, 1.40)
1.06 (0.65, 1.73)
0.54 (0.38, 0.77)
0.58 (0.40, 0.85)
0.78 (0.51, 1.20)
0.59 (0.38, 0.93)
0.73 (0.51, 1.06)
1.26 (0.60, 2.65)
0.63 (0.46, 0.88)
0.92 (0.36, 2.37)
0.78 (0.45, 1.35)
0.70 (0.45, 1.09)
0.33 (0.16, 0.69)
1.38 (0.67, 2.84)
0.68 (0.50, 0.93)
0.57 (0.29, 1.12)
FavoursApical Favoursnon-Apical
.125 1 8
CARDIAC MORTALITY
Apical better Apical worse
A
Figure 4. Subgroup analyses of outcomes according to longitudinal LV lead position. Risk of (A) cardiac
mortality and (B) total mortality according to longitudinal LV lead position, expressed as hazard ratios and
95% CI (horizontal lines), is shown for various subgroups of patients who received cardiac resynchronization
therapy. In the overall analysis, a LV apical lead position was associated with a hazard ratio of 0.66 (95% CI,
0.49–0.87) for cardiac mortality. CI indicates conﬁdence interval; CRT-D, cardiac resynchronization therapy
with deﬁbrillation; CRT-P, cardiac resynchronization therapy with pacing; LBBB, left bundle-branch block; LV,
left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; pts, patients.
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Clinical Implications
The ﬁndings from the subanalyses of the MADIT-CRT2 and
REVERSE3 studies indicating that an LV apical lead position is
less favorable than a nonapical position in CRT has been
noted in consensus statements.20 In MADIT-CRT, however, an
apical LV lead position was only “detrimental” in men, LBBB,
and nonischemic cardiomyopathy.2 Our ﬁndings, suggest that
LV apical pacing may be more favorable than nonapical
pacing, at least with respect to cardiac mortality. With respect
to total mortality, the effect was neutral rather than
detrimental. Although the ﬁndings of the present study are
limited by its observational nature, the ﬁndings from MADIT-
CRT and REVERSE are also limited by the study design of
subanalyses, which do not strictly equate with an intention-to
-treat analysis within the intended randomization. In the
absence of a randomized controlled trial for LV lead
positions, the decision of which LV position is most
appropriate in CRT currently rests on whether the patient
in question is better represented by subanalyses of
randomized controlled trials or by a study of “real-world”
patients, as described in this study.
Limitations
This article reports a 2-center, nonrandomized, retrospective,
observational study. In the absence of randomization, we
cannot exclude the possibility that unobserved variables may
have contributed to outcomes. As in randomized controlled
studies, the position of the LV lead was left to the discretion
of the implanter, and the reasons for choosing LV pacing sites
were not assessed. Our ﬁndings from ﬂuoroscopy do not
B
Figure 4. Continued.
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necessarily exclude the possibility that targeting LV pacing
sites using Q-LV or imaging techniques might have led to
different outcomes. We should also consider, however, that
these techniques were not used in MADIT-CRT2 or REVERSE.3
Although ﬂuoroscopy may not permit precise localization of
lead position, it has nevertheless been used in randomized
Table 5. Baseline Characteristics by Circumferential LV Lead Position
Anterior Lateral Posterior P Value
Patients, n 100 1027 62
Sex (male), n (%) 79 (79) 755 (73.52) 49 (79.03) 0.331
Age, y 7011.6 72.210.7 71.611.6 0.162
≤59 18 (18) 136 (13.24) 10 (16.13) 0.705
60–69 26 (26) 265 (25.80) 16 (25.81)
70–79 38 (38) 375 (36.51) 20 (32.26)
≥80 18 (18) 251 (24.44) 16 (25.81)
NYHA class, n (%)
I 1 (1.04) 36 (3.61) 1 (1.61) 0.613
II 5 (5.21) 66 (6.63) 6 (9.68)
III 81 (84.38) 778 (78.11) 47 (75.81)
IV 9 (9.38) 116 (11.65) 8 (12.90)
Device type, n (%)
CRT-D 42 (42) 451 (43.91) 21 (33.87) 0.291
CRT-P 58 (58) 576 (56.09) 41 (66.13)
Upgrade from pacemaker 19 (19) 180 (17.53) 4 (6.45) 0.069
Etiology of cardiomyopathy, n (%)
Ischemic 61 (61) 561 (54.63) 34 (54.84) 0.472
Nonischemic 39 (39) 466 (45.37) 28 (45.16)
Comorbidities, n (%)
Diabetes mellitus 20 (20) 230 (22.46) 7 (11.29) 0.107
Hypertension 25 (25) 306 (29.88) 9 (14.52) 0.024
CABG 17 (17) 194 (18.95) 12 (19.35) 0.887
ECG variables
Sinus rhythm, n (%) 67 (67) 687 (66.89) 42 (67.74) 0.990
Atrial fibrillation, n (%)† 33 (33) 340 (33.11) 20 (32.26)
QRS morphology (LBBB), n (%)‡ 77 (81.05) 808 (81.37) 46 (76.67) 0.665
QRS duration (ms)‡ 15320.2 155.622.8 153.222.3 0.412
Medication, n (%)
Loop diuretics 91 (91) 971 (94.55) 56 (90.32) 0.162
ACEI/ARB 86 (86) 890 (86.66) 53 (85.48) 0.953
b-blocker 66 (66) 686 (66.80) 46 (74.19) 0.470
MRA 28 (28) 451 (43.91) 24 (38.71) 0.007
LVEF (%) 23.58.8 24.59.8 239 0.376
Variables are expressed as meanSD unless indicated otherwise. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery
bypass grafting; CRT-D, cardiac resynchronization therapy with deﬁbrillation; CRT-P, cardiac resynchronization therapy with pacing; LBBB, left bundle-branch block; LV, left ventricular;
LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
*Refers to differences between the groups from ANOVA for continuous variables and from v2 tests for categorical variables.
†Includes permanent, persistent and paroxysmal atrial ﬁbrillation.
‡Excludes upgrades to pacemaker.
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controlled trials2,3,17 and is routinely used in clinical practice
worldwide.15,16
Conclusions
In this study of real-world clinical practice, an LV apical
position was associated with lower cardiac mortality than
nonapical positions, and a neutral effect was observed with
respect to total mortality. We found no difference in outcomes
among LV anterior, posterior, or lateral lead positions or
between RV septal and apical lead positions.
Sources of Funding
This study was supported by an unrestricted educational grant
from Boston Scientiﬁc. The sponsors had no input in the
design and conduct of the study; the collection, management,
analysis, or interpretation of the data; or the preparation,
review, or approval of the article.
Disclosures
Leyva has held consultancies with and has received research
funding from Medtronic Inc, Boston Scientiﬁc, St Jude Medical
and LivaNova. Patel has received speaker honoraria from
Medtronic Inc. Prinzen has received research grants from
Medtronic, Abbott, Biotronik, LivaNova, EBR Systems, Bio-
sense Webster. The remaining authors have no disclosures to
report.
References
1. Leyva F, Nisam S, Auricchio A. 20 years of cardiac resynchronization therapy. J
Am Coll Cardiol. 2014;64:1047–1058.
2. Singh JP, Klein HU, Huang DT, Reek S, Kuniss M, Quesada A, Barsheshet A,
Cannom D, Goldenberg I, McNitt S, Daubert JP, Zareba W, Moss AJ. Left
ventricular lead position and clinical outcome in the multicenter automatic
deﬁbrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT)
trial. Circulation. 2011;123:1159–1166.
3. Thebault C, Donal E, Meunier C, Gervais R, Gerritse B, Gold MR, Abraham WT,
Linde C, Daubert JC; group Rs. Sites of left and right ventricular lead
implantation and response to cardiac resynchronization therapy observations
from the reverse trial. Eur Heart J. 2012;33:2662–2671.
4. van Deursen C, van Geldorp IE, Rademakers LM, van Hunnik A, Kuiper M,
Klersy C, Auricchio A, Prinzen FW. Left ventricular endocardial pacing improves
resynchronization therapy in canine left bundle-branch hearts. Circ Arrhythm
Electrophysiol. 2009;2:580–587.
5. Peschar M, de Swart H, Michels KJ, Reneman RS, Prinzen FW. Left ventricular
septal and apex pacing for optimal pump function in canine hearts. J Am Coll
Cardiol. 2003;41:1218–1226.
6. Durrer D, van Dam RT, Freud GE, Janse MJ, Meijler FL, Arzbaecher RC. Total
excitation of the isolated human heart. Circulation. 1970;41:899–912.
7. Pluijmert M, Bovendeerd PH, Lumens J, Vernooy K, Prinzen FW, Delhaas T. New
insights from a computational model on the relation between pacing site and
CRT response. Europace. 2016;18:iv94–iv103.
8. Umar F, Taylor RJ, Stegemann B, Marshall H, Flannigan S, Lencioni M, De Bono
J, Grifﬁth M, Leyva F. Haemodynamic effects of cardiac resynchronization
therapy using single-vein, three-pole, multipoint left ventricular pacing in
patients with ischaemic cardiomyopathy and a left ventricular free wall scar:
the Maestro study. Europace. 2016;18:1227–1234.
9. National Institute of Health and Care Excellence. Nice technology appraisal [ta
314]: implantable cardioverter deﬁbrillators and cardiac resynchronisation
therapy for arrhythmias and heart failure (review of ta95 and ta120). 2014.
10. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In:
Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. New
York: WB Saunders Publishing Co; 1997:742–779.
11. Rockman HA, Juneau C, Chatterjee K, Rouleau JL. Long-term predictors of
sudden and low output death in chronic congestive heart failure secondary to
coronary artery disease. Am J Cardiol. 1989;64:1344–1348.
12. Kandala J, Upadhyay GA, Altman RK, Bose A, Heist EK, Mela T, Singh JP.
Electrical delay in apically positioned left ventricular leads and clinical
outcome after cardiac resynchronization therapy. J Cardiovasc Electrophysiol.
2013;24:182–187.
logrank P = .5760.00
0.25
0.50
0.75
1.00
E
ve
nt
 fr
ee
62 49 34 18 9 5 5 1Posterior
1027 789 532 288 118 34 14 2Lateral
100 76 54 31 15 5 2 0Anterior
Number at risk
0 2 4 6 8 10 12 14
Years
CARDIAC MORTALITY
Anterior
Lateral
Posterior
logrank P = .6390.00
0.25
0.50
0.75
1.00
E
ve
nt
 fr
ee
62 49 34 18 9 5 5 1Posterior
1027 789 532 288 118 34 14 2Lateral
100 76 54 31 15 5 2 0Anterior
Number at risk
0 2 4 6 8 10 12 14
Years
TOTAL MORTALITY
Anterior
Lateral
Posterior
CARDIAC MORTALITY TOTAL MORTALITY
Figure 5. Outcomes according to circumferential left ventricular lead position. Kaplan–Meier survival curves for cardiac mortality and total
mortality according to circumferential LV lead positions. CI indicates conﬁdence interval; CRT-D, cardiac resynchronization therapy with
deﬁbrillation; CRT-P, cardiac resynchronization therapy with pacing; LBBB, left bundle-branch block; LV, left ventricular; LVEF, left ventricular
ejection fraction; NYHA, New York Heart Association; pts, patients.
DOI: 10.1161/JAHA.117.008508 Journal of the American Heart Association 12
LV Lead Position in CRT Leyva et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on August 20, 2018
13. Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F, Auricchio A. Cardiac
resynchronization therapy guided by late gadolinium-enhancement cardiovas-
cular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:29.
14. Butter C, Auricchio A, Stellbrink C, Fleck E, Ding J, Yu Y, Huvelle E, Spinelli J.
Effect of resynchronization therapy stimulation site on the systolic function of
heart failure patients. Circulation. 2001;104:3026–3029.
15. Gasparini M, Mantica M, Galimberti P, Bocciolone M, Genovese L, Mangiavac-
chi M, Marchesina UL, Faletra F, Klersy C, Coates R, Gronda E. Is the left
ventricular lateral wall the best lead implantation site for cardiac resynchro-
nization therapy? Pacing Clin Electrophysiol. 2003;26:162–168.
16. Kronborg MB, Albertsen AE, Nielsen JC, Mortensen PT. Long-term clinical
outcome and left ventricular lead position in cardiac resynchronization
therapy. Europace. 2009;11:1177–1182.
17. Saxon LA, Olshansky B, Volosin K, Steinberg JS, Lee BK, Tomassoni G,
Guarnieri T, Rao A, Yong P, Galle E, Leigh J, Ecklund F, Bristow MR. Inﬂuence of
left ventricular lead location on outcomes in the companion study. J
Cardiovasc Electrophysiol. 2009;20:764–768.
18. Zografos TA, Siontis KC, Jastrzebski M, Kutyifa V, Klein HU, Zareba W, Katritsis
DG. Apical vs. non-apical right ventricular pacing in cardiac resynchronization
therapy: a meta-analysis. Europace. 2015;17:1259–1266.
19. Leclercq C, Sadoul N, Mont L, Defaye P, Osca J, Mouton E, Isnard R, Habib G,
Zamorano J, Derumeaux G, Fernandez-Lozano I. Comparison of right ventric-
ular septal pacing and right ventricular apical pacing in patients receiving
cardiac resynchronization therapy deﬁbrillators: the septal CRT study. Eur
Heart J. 2016;37:473–483.
20. Daubert JC, Saxon L, Adamson PB, Auricchio A, Berger RD, Beshai JF, Breithard
O, Brignole M, Cleland J, DeLurgio DB, Dickstein K, Exner DV, Gold M, Grimm
RA, Hayes DL, Israel C, Leclercq C, Linde C, Lindenfeld J, Merkely B, Mont L,
Murgatroyd F, Prinzen F, Saba SF, Shinbane JS, Singh J, Tang AS, Vardas PE,
Wilkoff BL, Zamorano JL, Anand I, Blomstrom-Lundqvist C, Boehmer JP, Calkins
H, Cazeau S, Delgado V, Estes NA, Haines D, Kusumoto F, Leyva P, Ruschitzka
F, Stevenson LW, Torp-Pedersen CT. 2012 EHRA/HRS expert consensus
statement on cardiac resynchronization therapy in heart failure: implant and
follow-up recommendations and management. Europace. 2012;14:1236–
1286.
DOI: 10.1161/JAHA.117.008508 Journal of the American Heart Association 13
LV Lead Position in CRT Leyva et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on August 20, 2018
SUPPLEMENTAL MATERIALDow
nloaded from
 http://ahajournals.org by on August 20, 2018
Figure S1. Clinical outcomes after cardiac resynchronization therapy according to lead position. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kaplan-Meier survival curves for clinical outcomes after CRT. MACE = major adverse cardiac events. 
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Figure S2. Mode of death according to left ventricular lead position.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kaplan-Meier survival curves for clinical outcomes after CRT according to longitudinal lead position. 
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 Figure S3. Mode of death according to left ventricular lead position: competing risks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kaplan-Meier survival curves for clinical outcomes after CRT using competing risk analysis. Mid and basal LV lead positions were grouped together. Solid lines refer to 
Kaplan-Meier survival estimates for the clinical endpoint. Dashed lines refer to Kaplan-Meier survival estimates using competing risks. 
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